hydroxychloroquine for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 mild to moderate meta-analysis
FACCT Trial NCT04392973		RCT	hydroxychloroquine	standard of care	COVID-19 mild to moderate	some concern	125/129	inconclusive	inconclusive 15 % decrease in clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine NCT04322123		RCT	hydroxychloroquine	standard of care	COVID-19 mild to moderate	some concern	221/227	safety concern	statistically significant 74 % increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
6 studies excluded by filtering options (5 RCT / 1 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 mild to moderate meta-analysis